`
`CLAIMS
`
`1. A pharmaceutical single-use, unit-dose formulation for intravenous
`administration to a human to reduce the likelihood of cancer chemotherapy-
`induced nausea and vomiting, comprising a 5 mL sterile aqueous isotonic
`solution, said solution comprising:
`
`5
`
`palonosetron hydrochloride in an amount of 0.25 mg based on the weight
`of its free base;
`
`from 0.005 mg/mL to 1.0 mg/mL EDTA; and
`
`10
`
`from 10 mg/mL to 80 mg/mL mannitol,
`
`wherein said formulation is stable at 24 months when stored at room
`temperature.
`
`2. The pharmaceutical formulation of claim 1, wherein said EDT A is in
`an amount of0.5 mg/mL.
`
`15
`
`3. The pharmaceutical formulation of claim 1, wherein said mannitol is in
`an amount of 41.5 tng/mL.
`
`4. The pharmaceutical formulation of claim 1, wherein said solution
`further comprises a citrate buffer.
`
`5. The pharmaceutical formulation of claim 4, wherein said citrate buffer
`is at a concentration of 20 millimolar.
`
`20
`
`6. The pharmaceutical formulation of claim 1, wherein said solution is
`buffered at a pH of 5.0 ± 0.5.
`
`7. The pharmaceutical formulation of claim 1, wherein said EDT A is in
`an amount of 0.5 mg/mL, wherein said mannitol is in an amount of 41.5 mg/mL,
`
`5579776vl 18
`
`Dr. Reddy’s Laboratories, Ltd., et al.
`v.
`Helsinn Healthcare S.A., et al.
`U.S. Patent No. 9,(cid:20)(cid:26)(cid:22),(cid:28)(cid:23)(cid:21)
`Reddy Exhibit 1050
`
`Exh. 1050
`
`
`
`wherein said solution further comprises a citrate buffer at a concentration of 20
`tnillitnolar, and wherein said solution is buffered at a pH of 5.0 ± 0.5.
`
`8. A pharmaceutical single-use, unit-dose formulation for intravenous
`administration to a human to reduce the likelihood of cancer chemotherapy-
`induced nausea and vomiting, comprising a 5 mL sterile aqueous isotonic
`solution, said solution comprising:
`
`5
`
`palonosetron hydrochloride in an amount of 0.25 mg based on the weight
`of its free base;
`
`from 0.005 mg/mL to 1.0 mg/mL EDTA; and
`
`10
`
`from 10 mg/mL to 80 mg/mL mannitol, wherein said formulation is stable
`at 18 months when stored at room temperature.
`
`9. A pharmaceutical single-use, unit-dose formulation for intravenous
`administration to a human to reduce the likelihood of cancer chemotherapy-
`induced nausea and vomiting, comprising a 50 mL sterile isotonic solution
`buffered at a pH of 4.8 ± 0.5 comprising:
`
`15
`
`palonosetron hydrochloride in an amount of 0.75 mg based on the weight
`of its free base;
`
`450.0 mg sodium chloride;
`
`2.5 mgEDTA;
`
`20
`
`18.5 mg sodium citrate; and
`
`7. 8 mg citric acid monohydrate,
`
`wherein said formulation is contained in a polyethylene multilayer film infusion
`bag comprising an isoprene rubber stopper.
`
`5579776vl 19
`
`Exh. 1050